Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study by Andreas Tiede, Robert Klamroth,

Slides:



Advertisements
Similar presentations
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Advertisements

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy by Chun.
One giant leap for pediatric AMKL
How I treat elderly patients with myeloma
An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim.
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients.
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival by Monika Führer, Udo Rampf, Irith Baumann, Andreas.
by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder
How we choose factor VIII to treat hemophilia
by Alexander Röth, Andreas Hüttmann, Russell P
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,
by Sabah Sallah, and Jim Y. Wan
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.
by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A
Stage C or not stage C…? by Claire Dearden Blood
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
by Michael F. Leahy, and J. Harvey Turner
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma by Robert Marcus, Kevin Imrie, Andrew Belch,
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
How I treat refractory CLL
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies by Sabine Kayser, Manuela Zucknick,
Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia — A Randomized Phase-III Study by.
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Overall survival by SCT versus observation in first complete remission
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas by Erin G. Reid, David Looney,
by Wendy Lim, Sara K. Vesely, and James N. George
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone,
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.
by Jan J. Cornelissen, and Didier Blaise
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients by Elena.
Cold agglutinin disease
New concepts for anticoagulant therapy in persons with hemophilia
 (A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy.  (A) Percentage of patients achieving remission.
Presentation transcript:

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study by Andreas Tiede, Robert Klamroth, Rüdiger E. Scharf, Ralf U. Trappe, Katharina Holstein, Angela Huth-Kühne, Saskia Gottstein, Ulrich Geisen, Joachim Schenk, Ute Scholz, Kristina Schilling, Peter Neumeister, Wolfgang Miesbach, Daniela Manner, Richard Greil, Charis von Auer, Manuela Krause, Klaus Leimkühler, Ulrich Kalus, Jan-Malte Blumtritt, Sonja Werwitzke, Eva Budde, Armin Koch, and Paul Knöbl Blood Volume 125(7): February 12, 2015 ©2015 by American Society of Hematology

Course and outcome of immunosuppressive therapy. *All 18 patients from the 2 sites not following the IST protocol were excluded regardless of their actual therapy. **Patients not yet achieving PR but continuously improving their FVIII activity until day Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology

Pathways to complete remission. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology

Adjusted time to PR and CR according to baseline FVIII activity. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology

Adjusted OS according to baseline characteristics. Andreas Tiede et al. Blood 2015;125: ©2015 by American Society of Hematology